Loading...
XETR
2HRA
, Last price  
Name

H&R GmbH & Co KgaA

Chart & performance

D1W1MN
XETR:2HRA chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
—
Rev. 5Y
7.17%
Div Yld LY
—
Div Yld TTM
—
Revenues
1.24b
-7.18%
1,232,246,0001,220,011,0001,063,988,000982,907,000942,653,0001,025,108,0001,114,148,0001,075,322,000878,539,0001,188,434,0001,576,043,0001,362,684,0001,338,240,0001,242,200,000
Net income
-39m
L
457,000-14,029,000-15,402,00026,903,00038,374,00032,131,00021,591,000-1,368,000-9,020,00050,176,00042,710,00010,556,00010,623,000-38,800,000
CFO
93m
+32.24%
84,660,00088,942,000-364,00056,548,00075,790,00046,519,00024,183,00096,067,00060,145,00037,570,00037,980,000119,715,00070,430,00093,137,000
Dividend
May 28, 20250.1 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

H&R GmbH & Co. KGaA is a German enterprise specializing in the production and distribution of chemical-pharmaceutical raw materials and precision plastic components, manufactured through injection molding. The company's operations are structured into three primary segments: ChemPharm Refining, ChemPharm Sales, and Plastics. The ChemPharm Refining division is responsible for manufacturing and supplying a diverse array of refined products, including paraffins, white oils, plasticizers, base oils, lubricants, and other specialized crude oil derivatives, as well as feedstocks and bunker fuels. Concurrently, the ChemPharm Sales segment focuses on the processing and commercialization of products such as plasticizers, wax emulsions, paraffins, and similar crude oil-based specialty items. The Plastics division is dedicated to the development, production, and sale of high-precision plastic parts tailored for industries like medical technology, automotive, and various other sectors. H&R's extensive product portfolio also encompasses petroleum jellies, different types of motor and process oils, cable filling compounds, ozone protection waxes, raw materials for the cosmetic and pharmaceutical sectors, mineral oils, and construction insulation materials. Founded in 1919 and headquartered in Salzbergen, Germany, the company transitioned its name to H&R GmbH & Co. KGaA in August 2016, having previously operated as H&R Aktiengesellschaft. It functions as a subsidiary of H&R Komplementär GmbH.

Related entities

Subsidiaries (6)
H&R ANZ PTY LTD
H&R Chemisch-Pharmazeutische Spezialitaten GmbH
H&R International GmbH
H&R Olwerke Schindler GmbH
H&R CHEMPHARM (UK) LIMITED
H&R South Africa (Pty) Ltd.

Key people

Joachim Girg
Chairman of the Supervisory Board · since 2012
Niels H. Hansen
Chairman of the Management Board, Chief Executive Officer · since 2016
Roland Chmiel
Independent Deputy Chairman of the Supervisory Board · since 2011
Detlev Woesten
Member of the Management Board · since 2016
Independent Member of the Supervisory Board · since 2019
Reinhold Grothus
Independent Member of the Supervisory Board, Employee Representative · since 2002
Sven Hansen
Member of the Supervisory Board · since 2016
Holger Hoff
Independent Member of the Supervisory Board, Employee Representative · since 2017
Harald Januszewski
Independent Member of the Supervisory Board, Employee Representative · since 2012
Hartmut Schuetter
Independent Member of the Supervisory Board · since 2013
Rolf Schwedhelm
Independent Member of the Supervisory Board · since 2011
IPO date
Dec 21, 1953
Employees
1,671
Domiciled in
DE
Incorporated in
DE
Headquarters & legal address
Neuenkirchener Str. 8
Salzbergen, NI 48499
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT